New Drugs for Treating Dyslipidemia: Beyond Statins.
- Author:
Chang Ho AHN
1
;
Sung Hee CHOI
Author Information
- Publication Type:Review
- Keywords: Dyslipidemia; MTP inhibitor; PCSK9 inhibitor
- MeSH: Apolipoprotein A-I; Apolipoproteins; Apolipoproteins B; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Dyslipidemias*; Hepatocytes; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors*; Hyperlipoproteinemia Type II; Lipoproteins; Receptors, LDL; Recycling; Triglycerides
- From:Diabetes & Metabolism Journal 2015;39(2):87-94
- CountryRepublic of Korea
- Language:English
- Abstract: Statins have been shown to be very effective and safe in numerous randomized clinical trials, and became the implacable first-line treatment against atherogenic dyslipidemia. However, even with optimal statin treatment, 60% to 80% of residual cardiovascular risk still exists. The patients with familial hypercholesterolemia which results in extremely high level of low density lipoprotein cholesterol (LDL-C) level and the patients who are intolerant or unresponsive to statins are the other hurdles of statin treatment. Recently, new classes of lipid-lowering drugs have been developed and some of them are available for the clinical practice. The pro-protein convertase subtilisin/kexintype 9 (PCSK9) inhibitor increases the expression of low density lipoprotein (LDL) receptor in hepatocytes by enhancing LDL receptor recycling. The microsomal triglyceride transport protein (MTP) inhibitor and antisense oligonucleotide against apolipoprotein B (ApoB) reduce the ApoB containing lipoprotein by blocking the hepatic very low density lipoprotein synthesis pathway. The apolipoprotein A1 (ApoA1) mimetics pursuing the beneficial effect of high density lipoprotein cholesterol and can reverse the course of atherosclerosis. ApoA1 mimetics had many controversial clinical data and need more validation in humans. The PCSK9 inhibitor recently showed promising results of significant LDL-C lowering in familial hypercholesterolemia (FH) patients from the long-term phase III trials. The MTP inhibitor and antisesnse oligonucleotide against ApoB were approved for the treatment of homozygous FH but still needs more consolidated evidences about hepatic safety such as hepatosteatosis. We would discuss the benefits and concerns of these new lipid-lowering drugs anticipating additional benefits beyond statin treatment.
